Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs. It also designs, manufactures, and sells neural interface technologies, including microelectrode arrays, custom designed probes, and electrode instrumentation and accessories; and develops Virtis, a sacral neuromodulation system for the treatment of chronic urinary retention and overactive bladder. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone214-474-3103
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.84 million
Profitability
Miscellaneous
Employees195
OptionableOptionable
Nuvectra (NASDAQ:NVTR) Frequently Asked Questions
What is Nuvectra's stock symbol?
Nuvectra trades on the NASDAQ under the ticker symbol "NVTR."
How were Nuvectra's earnings last quarter?
Nuvectra Corp (NASDAQ:NVTR) announced its quarterly earnings data on Monday, October, 29th. The company reported ($0.87) EPS for the quarter, missing the Zacks' consensus estimate of ($0.86) by $0.01. The firm earned $14.22 million during the quarter, compared to analyst estimates of $12.38 million. Nuvectra had a negative net margin of 87.94% and a negative return on equity of 65.86%. View Nuvectra's Earnings History.
When is Nuvectra's next earnings date?
What guidance has Nuvectra issued on next quarter's earnings?
Nuvectra issued an update on its FY 2018 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $53.2-53.6 million, compared to the consensus revenue estimate of $52.94 million.Nuvectra also updated its Q4 2018 guidance to EPS.
What price target have analysts set for NVTR?
4 Wall Street analysts have issued twelve-month price objectives for Nuvectra's shares. Their forecasts range from $21.00 to $27.00. On average, they expect Nuvectra's stock price to reach $24.00 in the next year. This suggests a possible upside of 71.3% from the stock's current price. View Analyst Price Targets for Nuvectra.
What is the consensus analysts' recommendation for Nuvectra?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra.
Has Nuvectra been receiving favorable news coverage?
News headlines about NVTR stock have been trending very positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nuvectra earned a news impact score of 3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are some of Nuvectra's key competitors?
Some companies that are related to Nuvectra include Orthofix Medical (OFIX), Intersect ENT (XENT), AngioDynamics (ANGO), Cerus (CERS), OraSure Technologies (OSUR), SurModics (SRDX), SI-Bone (SIBN), Anika Therapeutics (ANIK), Inovio Pharmaceuticals (INO), Antares Pharma (ATRS), LeMaitre Vascular (LMAT), Orthopediatrics (KIDS), Axonics Modulation Technologies (AXNX), GenMark Diagnostics (GNMK) and Accuray (ARAY).
Who are Nuvectra's key executives?
Nuvectra's management team includes the folowing people:
- Mr. Scott F. Drees, CEO & Director (Age 61)
- Mr. Joseph Paul Hanchin, Pres (Age 57)
- Mr. Walter Z. Berger, COO, CFO & Exec. VP (Age 63)
- Ms. Jennifer J. Kosharek, VP, Controller & Principal Accounting Officer (Age 38)
- Mr. Benjamin Tranchina, Chief Technology Officer
Who are Nuvectra's major shareholders?
Nuvectra's stock is owned by a number of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (3.77%). Company insiders that own Nuvectra stock include Joseph A Miller, Joseph Paul Hanchin, Scott F Drees and Thomas Edward Zelibor. View Institutional Ownership Trends for Nuvectra.
Which institutional investors are buying Nuvectra stock?
NVTR stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have bought Nuvectra stock in the last two years include Joseph A Miller, Scott F Drees and Thomas Edward Zelibor. View Insider Buying and Selling for Nuvectra.
How do I buy shares of Nuvectra?
Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nuvectra's stock price today?
One share of NVTR stock can currently be purchased for approximately $14.01.
How big of a company is Nuvectra?
Nuvectra has a market capitalization of $246.70 million and generates $31.84 million in revenue each year. The company earns $-44,600,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis. Nuvectra employs 195 workers across the globe.
What is Nuvectra's official website?
How can I contact Nuvectra?
Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected]
MarketBeat Community Rating for Nuvectra (NASDAQ NVTR)
MarketBeat's community ratings are surveys of what our community members think about Nuvectra and other stocks. Vote "Outperform" if you believe NVTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
